OptimizeRx Posts Record Q4 EBITDA $12M, Lifts 2026 Guidance, Approves $10M Buyback
OptimizeRx delivered Q4 2025 revenue of $32.2M, gross profit up 9% to $24.1M, record net income of $5.0M and adjusted EBITDA of $12.0M. The company now forecasts 2026 revenue of $109–$114M, adjusted EBITDA of $21–$25M, paid down $2M of term debt and approved a $10M share repurchase program.
1. Q4 2025 Financial Results
OptimizeRx reported Q4 revenue of $32.2 million, stable year-over-year, with gross profit rising 9% to $24.1 million. GAAP net income reached $5.0 million ($0.26 per diluted share) and adjusted EBITDA set a record at $12.0 million.
2. Full Year 2025 Performance
Full year revenue climbed 19% to $109.4 million, while full year gross profit increased to $73.6 million. GAAP net income was $5.1 million ($0.27 per diluted share), non-GAAP net income was $19.9 million ($1.05 per share), and adjusted EBITDA nearly doubled to $24.3 million.
3. 2026 Financial Outlook
Management updated 2026 revenue guidance to a range of $109 million to $114 million and forecasts adjusted EBITDA between $21 million and $25 million, targeting sustained profitability under the Rule of 40 framework.
4. Debt Reduction and Share Repurchase
During Q4 the company paid down $2 million in term loan principal, ending the year with $23.4 million in cash. The board authorized a $10 million share repurchase program effective through March 2027.